Xlife Sciences AG Total Assets
Xlife Sciences AG total assets. Based on the latest financial reports, Xlife Sciences AG (XLS) holds total assets worth CHF517.12 Million CHF (≈ $653.78 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Xlife Sciences AG stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Xlife Sciences AG (2019–2025)
Total assets of Xlife Sciences AG from 2019 to 2025. This chart illustrates how Xlife Sciences AG's total assets have evolved over time, based on quarterly financial data. See Xlife Sciences AG share price for real-time trading data and today's change.
Xlife Sciences AG - Asset Composition Analysis
Xlife Sciences AG Total Assets Breakdown (December 2025)
Xlife Sciences AG total assets breakdown as of December 2025. Xlife Sciences AG's total assets of CHF517.12 Million consist of 0.3% current assets and 99.7% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0.1% |
| Accounts Receivable | CHF93.63K | 0.0% |
| Inventory | CHF29.26K | 0.0% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF253.68 Million | 49.1% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Xlife Sciences AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Xlife Sciences AG (XLS) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xlife Sciences AG's current assets represent 0.3% of total assets in 2025, a decrease from 3.3% in 2019.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2025, up from 0.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 49.1% of total assets.
Xlife Sciences AG Competitors by Total Assets
Key competitors of Xlife Sciences AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Xlife Sciences AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.10 | 1.53 | 1.60 |
| Quick Ratio | 0.10 | 1.53 | 1.60 |
| Cash Ratio | 0.00 | 0.01 | 1.50 |
| Working Capital | CHF-13.38 Million | CHF4.95 Million | CHF1.89 Million |
Xlife Sciences AG - Advanced Valuation Insights
This section examines the relationship between Xlife Sciences AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.26 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -4.3% |
| Total Assets | CHF517.12 Million |
| Market Capitalization | $65.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xlife Sciences AG's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Xlife Sciences AG's assets decreased by 4.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Xlife Sciences AG (2019–2025)
The table below shows the annual total assets of Xlife Sciences AG from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF517.12 Million ≈ $653.78 Million |
-4.30% |
| 2024-12-31 | CHF540.37 Million ≈ $683.18 Million |
+5.54% |
| 2023-12-31 | CHF511.99 Million ≈ $647.30 Million |
+4.44% |
| 2022-12-31 | CHF490.23 Million ≈ $619.78 Million |
+2.12% |
| 2021-12-31 | CHF480.06 Million ≈ $606.93 Million |
+158.54% |
| 2020-12-31 | CHF185.68 Million ≈ $234.75 Million |
+20.56% |
| 2019-12-31 | CHF154.02 Million ≈ $194.72 Million |
-- |
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinica… Read more